Drug profile

The FDA adverse-event record for Bacitracin, Neomyxin & Polymyxin B

14 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Bacitracin, Neomyxin & Polymyxin B. See the species affected, top reactions, and outcomes below.

14
adverse-event reports
14.3%
death-coded share
Dog
most-reported species
7
Lethargy (see also Central nervous system depression in 'Neurological') - top reaction
Verify with FDA CVM →
Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
14
Total Reports
2
Deaths Reported
14.3%
Death Rate

Active Ingredients

Bacitracin, Neomyxin & Polymyxin B

Administration Routes

TopicalOphthalmic

Species Affected

Dog 7
Cat 6
Camel 1

Most Affected Breeds

Domestic Shorthair 6
Shepherd Dog - Anatolian 1
Terrier - Yorkshire 1
Retriever - Golden 1
Pekingese 1
Unknown 1
Terrier - Boston 1
Shih Tzu 1
Poodle - Toy 1

Most Reported Reactions

Lethargy (see also Central nervous system depression in 'Neurological') 7
Anorexia 5
Other abnormal test result NOS 3
Heart murmur 3
Injection site lump 3
Anaemia NOS 3
Application site alopecia 3
Eye redness 2
Death by euthanasia 2
Application site erythema 2
Skin lesion NOS 2
Erythema (for urticaria see Immune SOC) 2

Outcome Breakdown

Ongoing
7 (50.0%)
Outcome Unknown
3 (21.4%)
Euthanized
2 (14.3%)
Recovered/Normal
2 (14.3%)

Bacitracin, Neomyxin & Polymyxin B Adverse Event Insights

14 reports name Bacitracin, Neomyxin & Polymyxin B; 2 recorded a death outcome (14.3% of reported events, not a population-level mortality rate). Active ingredient: Bacitracin, Neomyxin & Polymyxin B. Administration routes: Topical, Ophthalmic.

By species: Dog (7 reports), Cat (6 reports), Camel (1 reports). By breed: Domestic Shorthair (6), Shepherd Dog - Anatolian (1), Terrier - Yorkshire (1).

Leading clinical signs: Lethargy (see also Central nervous system depression in 'Neurological') (7), Anorexia (5), Other abnormal test result NOS (3), Heart murmur (3). Outcome, 14 coded reports: Ongoing leads at 50.0%.

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

Every figure on PlainBreed is rendered directly from FDA openFDA adverse event data, no number is typed in by an editor. This page draws directly on FDA openFDA data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.